-
Oct 9, 2024 | 
ascpt.onlinelibrary.wiley.com | Austin Jones |Outcomes Science |Elias Rosen |Kara M. Rademeyer
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Despite the effectiveness of combination antiretroviral therapy in suppressing HIV peripherally, neuroHIV remains a challenge. Concurrent opioid use exacerbates neuroHIV by increasing neuroinflammation, neuronal injury, cognitive deficits, and altering antiretroviral concentrations in the brain. The interactions between HIV proteins, like Tat, opioids, and antiretrovirals significantly impact drug distribution and effectiveness within the brain.
-
Jul 18, 2024 | 10968-0/abstract&sz=64)
ajpe.org | Caitlin Gibson |Outcomes Science |Matthew Lacroix |Kirk E. Hevener
Professional pharmacy fraternal organizations are among the most common student organizations in schools and colleges of pharmacy, present on 98% of campuses. However, sparse literature explores the educational value these organizations offer. The purpose of this review is to explore the alignment of national requirements of two major pharmacy fraternities with co-curricular learning objectives.
-
Jul 5, 2024 | 10473-1/abstract&sz=64)
ajpe.org | Omar Attarabeen |Osama A Shoair |Outcomes Science |Fadi L. Alkhateeb
Footnotes2 ORCID ID: 0000-0002-2078-299XAffiliationsPharmacotherapy and Outcomes Science, The University of Texas at Tyler Fisch College of Pharmacy, 3900 University Blvd, Tyler, TX 75799
-
Feb 28, 2024 | 
karger.com | Umm Al Qura |Yahya M.K |Outcomes Science
Keywords:
Implementation,
SGLT2 inhibitors,
Population health
Individuals with chronic kidney disease (CKD) have an increased risk of estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (hereafter referred to as CKD progression), and heart failure (HF) compared to the general population [1].
-
Feb 8, 2024 | 
journals.plos.org | Outcomes Science |Jessica IChi Lai |Christina Kim |Amir M. Behdani
Citation: Behdani AM, Lai J, Kim C, Basalelah L, Halsey T, Donohoe KL, et al. (2024) Optimizing pharmacogenomic decision-making by data science. PLOS Digit Health 3(2): e0000451. https://doi.org/10.1371/journal.pdig.0000451Editor: Nino Isakadze, Johns Hopkins Medicine, UNITED STATESReceived: March 27, 2023; Accepted: January 17, 2024; Published: February 8, 2024Copyright: © 2024 Behdani et al.
-
Dec 8, 2023 | 
onlinelibrary.wiley.com | Lana Sargent |Outcomes Science |Andrew Singleton
ACB Anticholinergic Cognitive Burden ALT alanine aminotransferase ARIC Atherosclerosis Risk in Communities Study AUC area under the curve CES-D Center for Epidemiologic Studies Depression Scale CHS Cardiovascular Health Study FN false negatives FP false positives HR hazard ratios IL-6 interleukin-6 InCHIANTI Study Invecchiare in Chianti ML machine learning ROC receiver operating characteristic TN true negatives TNFR 1 & 2 soluble TNF-a receptor I and II TP true positives 1 INTRODUCTION There...
-
Nov 3, 2023 | 
jamanetwork.com | Dave Dixon |Outcomes Science |Karissa Johnston |Outcomes Research
Key PointsQuestion What would be the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the United States? Findings In this simulated cost-effectiveness analysis of a 5-state Markov model, 50% uptake of a pharmacist-prescribing intervention to improve blood pressure control was associated with a $1.137 trillion in cost savings and could save an estimated 30.2 million life years over 30 years.
-
Jun 1, 2023 | 
frontiersin.org | Outcomes Science |Virginia Commonwealth
Youssef M. Roman1*
1Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, United States
The final, formatted version of the article will be published soon.
-
May 18, 2023 | 
bpspubs.onlinelibrary.wiley.com | Ya-Feng Wen |Richard C. Brundage |Youssef M Roman |Outcomes Science
ORIGINAL ARTICLE Funding information: This work was supported by the University of Minnesota, Office of Community Engagement of the Clinical and Translational Science Institute for its funding via 2014 Collaborative Pilot Grants No. 22556 and National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114.
-
Mar 25, 2023 | 
diabetesjournals.org | Van Tassell |Outcomes Science |Yahya M.K
To determine the effects of intensive systolic blood pressure (SBP) lowering on the risk of major adverse kidney outcomes in people with type 2 diabetes mellitus (T2DM) and/or prediabetes and cardiovascular risk factors. This post hoc ACCORD-BP subgroup analysis included participants in the standard glucose-lowering arm with cardiovascular risk factors required for SPRINT eligibility.
